论文部分内容阅读
Targeting cancer metabolism is emerging as a successful strategy for cancer therapy [1].However,most marketed anti-metabolism drugs in cancer therapy do not distinguish normal cells from cancer cells,leading to severe side effects.Glucose metabolism is elevated in microenvironmental conditions associated with poor vascular supply,such as hypoxia and reduced extracellular pH.Glucose Transporter 3 (GLUT3),essential for tumor glucose uptake,is highly expressed by glioma cells and glioma stem cells [2].We propose to develop nano-sized system to deliver siRNA targeting GLUT3 in cancer cell and cancer stem cell,aiming at high specificity and reduced side effects.